{"DataElement":{"publicId":"7524441","version":"1","preferredName":"Biosimilar Agent Administered Name","preferredDefinition":"The name of the biosimilar agent administered.","longName":"7522035v1.0:7522040v1.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"7522035","version":"1","preferredName":"Biosimilar Agent Administered","preferredDefinition":"A biological product that is highly similar in structure and function to, and has no clinically meaningful differences from, an FDA-approved reference product._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._The act of having given something (e.g., a medication or test).","longName":"7522033v1.0:2233610v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"7522033","version":"1","preferredName":"Biosimilar Agent","preferredDefinition":"A biological product that is highly similar in structure and function to, and has no clinically meaningful differences from, an FDA-approved reference product.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"C156644:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biosimilar","conceptCode":"C156644","definition":"A biological product that is highly similar in structure and function to, and has no clinically meaningful differences from, an FDA-approved reference product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B59520A7-E021-3DB6-E053-4EBD850ACDB3","latestVersionIndicator":"Yes","beginDate":"2020-12-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B59520A7-E02F-3DB6-E053-4EBD850ACDB3","latestVersionIndicator":"Yes","beginDate":"2020-12-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-12-03","modifiedBy":"MORENOC","dateModified":"2021-04-28","changeDescription":"4/28/2021: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7522040","version":"1","preferredName":"Biosimilar Agent Administered Name","preferredDefinition":"The name of the biosimilar agent administered.","longName":"7522040v1.0","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Bevacizumab-awwb (MVASI)","valueDescription":"Bevacizumab","ValueMeaning":{"publicId":"4916311","version":"1","preferredName":"Bevacizumab","longName":"4916311","preferredDefinition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B693509-9093-B947-E050-BB89AD43520F","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B595D8FD-A28B-4A5C-E053-4EBD850A696F","beginDate":"2020-12-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-12-04","modifiedBy":"ONEDATA","dateModified":"2020-12-04","deletedIndicator":"No"},{"value":"Bevacizumab-bvzr (Zirabev)","valueDescription":"Bevacizumab","ValueMeaning":{"publicId":"4916311","version":"1","preferredName":"Bevacizumab","longName":"4916311","preferredDefinition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B693509-9093-B947-E050-BB89AD43520F","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B595D8FD-A29F-4A5C-E053-4EBD850A696F","beginDate":"2020-12-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-12-04","modifiedBy":"ONEDATA","dateModified":"2020-12-04","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559666","version":"1","preferredName":"Other","longName":"2559666","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B61F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"LISU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B595C26D-2DFC-4CF6-E053-4EBD850AD7C2","beginDate":"2020-12-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-12-03","modifiedBy":"ONEDATA","dateModified":"2020-12-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B595C26D-2DE6-4CF6-E053-4EBD850AD7C2","latestVersionIndicator":"Yes","beginDate":"2020-12-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-12-03","modifiedBy":"MORENOC","dateModified":"2021-04-28","changeDescription":"4/28/2021: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Specify biosimilar agent name","type":"Preferred Question Text","description":"Specify biosimilar agent name","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5939FD7-779E-709F-E053-4EBD850A429E","latestVersionIndicator":"Yes","beginDate":"2020-12-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-12-04","modifiedBy":"MORENOC","dateModified":"2021-04-28","changeDescription":"4/28/2021: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}